Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Molecular and Cellular Biochemistry

• Publication date

  2021-04-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11010-021-04152-yPMID 33835331
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime?

  2020cited by this paper
• The Cardioprotective Role of Flaxseed in the Prevention of Doxorubicin- and Trastuzumab-Mediated Cardiotoxicity in C57BL/6 Mice.

  2020cited by this paper
• The Prophylactic Effect of Pinocembrin Against Doxorubicin-Induced Cardiotoxicity in an In Vitro H9c2 Cell Model

  2020cited by this paper
• Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors

  2019cited by this paper
• Breast Cancer: Current Perspectives on the Disease Status.

  2019cited by this paper
• Atorvastatin protects cardiomyocyte from doxorubicin toxicity by modulating survivin expression through FOXO1 inhibition.

  2019influential reference
• Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes.

  2019cited by this paper
• Breast Cancer: Current Perspectives on the Disease Status.

  2019cited by this paper
• Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association.

  2019cited by this paper
• Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series

  2019cited by this paper
• Oxidative stress injury in doxorubicin-induced cardiotoxicity.

  2019cited by this paper
• Effect of Rosuvastatin in Preventing Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer: A Randomized, Single-Blind, Placebo-Controlled Trial

  2019cited by this paper
• Atorvastatin Improves Doxorubicin-Induced Cardiac Dysfunction by Modulating Hsp70, Akt, and MAPK Signaling Pathways

  2019cited by this paper
• Carvedilol (CAR) combined with carnosic acid (CAA) attenuates doxorubicin-induced cardiotoxicity by suppressing excessive oxidative stress, inflammation, apoptosis and autophagy.

  2019influential reference
• Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin

  2018cited by this paper
• Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity

  2018cited by this paper
• Nanoceria ameliorates doxorubicin induced cardiotoxicity: Possible mitigation via reduction of oxidative stress and inflammation.

  2018cited by this paper
• Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling.

  2018cited by this paper
• Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.

  2018cited by this paper
• Flaxseed Lignans Enhance the Cytotoxicity of Chemotherapeutic Agents against Breast Cancer Cell Lines MDA-MB-231 and SKBR3

  2018cited by this paper
• Nrf2 at the heart of oxidative stress and cardiac protection.

  2018influential reference
• Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer

  2018cited by this paper
• Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review

  2018influential reference
• Anthracycline Chemotherapy and Cardiotoxicity

  2017influential reference
• Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers

  2017cited by this paper
• Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity

  2017cited by this paper
• Oxidative Stress and Cellular Response to Doxorubicin: A Common Factor in the Complex Milieu of Anthracycline Cardiotoxicity

  2017cited by this paper
• Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention

  2017cited by this paper
• Antioxidant Therapeutic Strategies for Cardiovascular Conditions Associated with Oxidative Stress

  2017cited by this paper
• Vitamin C mitigates oxidative/nitrosative stress and inflammation in doxorubicin-induced cardiomyopathy.

  2017cited by this paper
• Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy

  2017cited by this paper
• Time course of changes in oxidative stress and stress-induced proteins in cardiomyocytes exposed to doxorubicin and prevention by vitamin C

  2017cited by this paper
• Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite.

  2017cited by this paper
• Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial

  2016cited by this paper
• Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.

  2016cited by this paper
• Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol

  2016cited by this paper
• Aerobic Exercise Training as a Potential Cardioprotective Strategy to Attenuate Doxorubicin-Induced Cardiotoxicity.

  2016cited by this paper
• The Cardioprotective Role of N-Acetyl Cysteine Amide in the Prevention of Doxorubicin and Trastuzumab-Mediated Cardiac Dysfunction.

  2016cited by this paper
• Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy

  2015cited by this paper
• DNA Topoisomerases

  2015cited by this paper
• Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up.

  2014cited by this paper
• Can the epirubicin cardiotoxicity in cancer patients be prevented by angiotensin converting enzyme inhibitors?

  2013cited by this paper
• Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study.

  2013cited by this paper
• ARB and Cardioprotection

  2013cited by this paper
• Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate

  2013cited by this paper
• Nutrition and physical activity guidelines for cancer survivors

  2012cited by this paper
• Pretreatment effect of running exercise on HSP70 and DOX-induced cardiotoxicity.

  2012influential reference
• Identification of the molecular basis of doxorubicin-induced cardiotoxicity

  2012cited by this paper
• Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function.

  2011cited by this paper
• The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity.

  2011cited by this paper
• ACE inhibitors – angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease

  2010cited by this paper
• High-oleic rapeseed (canola) and flaxseed oils modulate serum lipids and inflammatory biomarkers in hypercholesterolaemic subjects

  2010cited by this paper
• Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats.

  2010cited by this paper
• Regulation of mitochondrial biogenesis.

  2010cited by this paper
• Short-term exercise training protects against doxorubicin-induced cardiac mitochondrial damage independent of HSP72.

  2010influential reference
• Dietary flaxseed prevents radiation-induced oxidative lung damage, inflammation and fibrosis in a mouse model of thoracic radiation injury

  2009cited by this paper
• DNA Topoisomerases

  2009influential reference
• N-acetylcysteine amide decreases oxidative stress but not cell death induced by doxorubicin in H9c2 cardiomyocytes

  2009cited by this paper
• Meta-analysis of the effects of flaxseed interventions on blood lipids.

  2009influential reference
• Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy

  2008cited by this paper
• Exercise induces a cardiac mitochondrial phenotype that resists apoptotic stimuli.

  2008influential reference
• Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives

  2008cited by this paper
• Antioxidant activities of the flaxseed lignan secoisolariciresinol diglucoside, its aglycone secoisolariciresinol and the mammalian lignans enterodiol and enterolactone in vitro.

  2007cited by this paper
• Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management.

  2007cited by this paper
• Anti-inflammatory Effect of α-Linolenic Acid and Its Mode of Action through the Inhibition of Nitric Oxide Production and Inducible Nitric Oxide Synthase Gene Expression via NF-κB and Mitogen-Activated Protein Kinase Pathways

  2007cited by this paper
• Anti-inflammatory effect of alpha-linolenic acid and its mode of action through the inhibition of nitric oxide production and inducible nitric oxide synthase gene expression via NF-kappaB and mitogen-activated protein kinase pathways.

  2007cited by this paper
• Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity.

  2006cited by this paper
• Protective effects of carvedilol against anthracycline-induced cardiomyopathy.

  2006cited by this paper
• Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition

  2006cited by this paper
• Endurance training attenuates doxorubicin-induced cardiac oxidative damage in mice.

  2005cited by this paper
• Mechanisms for the clinical benefits of angiotensin II receptor blockers.

  2005influential reference
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update

  2005cited by this paper
• Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro.

  2004cited by this paper
• Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity

  2004cited by this paper
• New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity

  2003cited by this paper
• Potential protective role of angiotensin‐converting enzyme inhibitors captopril and enalapril against adriamycin‐induced acute cardiac and hepatic toxicity in rats

  2001cited by this paper
• Status of myocardial antioxidants in ischemia-reperfusion injury.

  2000cited by this paper
• Angiotensin II receptor antagonists.

  2000cited by this paper
• A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.

  1999cited by this paper
• Enalapril and captopril enhance antioxidant defenses in mouse tissues.

  1997cited by this paper
• Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

  1997cited by this paper
• [Angiotensin II receptor antagonists].

  1995cited by this paper
• Molecular and cellular biochemistry

  1994cited by this paper
• The Scavenging of Oxygen Free Radicals by Angiotensin Converting Enzyme Inhibitors: The Importance of the Sulfhydryl Group in the Chemical Structure of the Compounds

  1994cited by this paper
• The scavenging of oxygen free radicals by angiotensin converting enzyme inhibitors: the importance of the sulfhydryl group in the chemical structure of the compounds.

  1994cited by this paper
• Effect of captopril on the cytological and biochemical changes induced by adriamycin.

  1993cited by this paper
• Captopril: a free radical scavenger.

  1989cited by this paper
• Downloaded from http://circres.ahajournals.org / by guest on February 23, 2013Peroxynitrite Is a Major Contributor to Cytokine-Induced

  year unknowncited by this paper

• Diet quality and cardiometabolic health in breast cancer survivors: the Pathways Study

  2025cites this paper
• Chemotherapy-Induced Cardiotoxicity: Mechanisms, Detection and Emerging Therapies in Cardio-Oncology

  2025cites this paper
• Cancer Therapy-Related Left Ventricular Dysfunction: Are There New Gatekeepers?

  2025cites this paper
• Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update

  2025cites this paper
• Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology

  2025cites this paper
• Cancer-Therapy-Related Cardiac Dysfunction: Latest Advances in Prevention and Treatment

  2025cites this paper
• What intensivists need to know on cardiac dysfunction in critically ill cancer patients

  2024cites this paper
• Incidence of chemotherapy‐related cardiac dysfunction in cancer patients

  2024cites this paper
• Dioxime palladium (II) complex: Synthesis, characterization, and dual anticancer mechanisms of topoisomerase II inhibition and Bax/caspase 3

  2024cites this paper
• Statins for the Primary Prevention of Anthracycline Cardiotoxicity: A Comprehensive Review

  2024cites this paper
• Changes in Epicardial Adipose Tissue Assessed by Chest CT in Breast Cancer Patients Receiving Adjuvant Chemotherapy with Anthracyclines and Trastuzumab

  2024cites this paper
• Previous treatment with anthracycline does not affect the course of sepsis in cancer patients: Retrospective cohort study

  2024cites this paper
• Accuracy of mitral annular plane systolic excursion in diagnosing anthracycline-induced subclinical cardiotoxicity in patients with breast cancer - a retrospective cohort study

  2024cites this paper
• Left ventricular myocardial performance index (Tei index) as an early marker of cardiotoxicity in antitumor therapy

  2024cites this paper
• Neoadjuvant Chemotherapy of Taxanes With or Without Anthracyclines in Different Molecular Subtypes of Breast Cancer: A Propensity Score Matching Study.

  2023cites this paper
• Preventing broken hearts in women with breast cancer: A concise review on chemotherapy-mediated cardiotoxicity.

  2023cites this paper
• Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?

  2023cites this paper
• Anthracycline cardiotoxicity: current methods of diagnosis and possible role of 18F-FDG PET/CT as a new biomarker

  2023influential citation
• Targeting heat shock protein 47 alleviated doxorubicin-induced cardiotoxicity and remodeling in mice through suppression of the NLRP3 inflammasome.

  2023cites this paper
• Birth Outcomes of Anticancer Drug Prescriptions during Pregnancy: A Case Series from a Japanese Claims Database

  2023cites this paper
• Diagnosis and Management of Cancer Treatment-Related Cardiac Dysfunction and Heart Failure in Children

  2023cites this paper
• Cardioprotective Mechanism and Active Compounds of Folium Ginkgo on Adriamycin-Induced Cardiotoxicity: A Network Pharmacology Study

  2022cites this paper
• Can Dietary Nutrients Prevent Cancer Chemotherapy-Induced Cardiotoxicity? An Evidence Mapping of Human Studies and Animal Models

  2022cites this paper
• The Role of Cardioprotection in Cancer Therapy Cardiotoxicity

  2022cites this paper
• Mitochondrial targeted antioxidants, mitoquinone and SKQ1, not vitamin C, mitigate doxorubicin-induced damage in H9c2 myoblast: pretreatment vs. co-treatment

  2021cites this paper
• Anthracycline-induced cardiomyopathy: Is there a new light at the end of the tunnel?

  2021cites this paper
• Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors

  2021cites this paper